TRI LO SPRINTEC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tri Lo Sprintec, and what generic alternatives are available?
Tri Lo Sprintec is a drug marketed by Barr Labs Inc and is included in one NDA.
The generic ingredient in TRI LO SPRINTEC is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRI LO SPRINTEC?
- What are the global sales for TRI LO SPRINTEC?
- What is Average Wholesale Price for TRI LO SPRINTEC?
Summary for TRI LO SPRINTEC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Clinical Trials: | 2 |
DailyMed Link: | TRI LO SPRINTEC at DailyMed |
Recent Clinical Trials for TRI LO SPRINTEC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Pennsylvania | Phase 1 |
Society of Family Planning | Phase 1 |
American Heart Association | Phase 4 |
US Patents and Regulatory Information for TRI LO SPRINTEC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Barr Labs Inc | TRI LO SPRINTEC | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 076784-001 | Jun 29, 2009 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |